Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
Year: 2019
Type: article
Abstract: The increasing worldwide prevalence of Hepatocellular carcinoma (HCC), characterized by resistance to conventional chemotherapy, poor prognosis and eventually mortality, place it as a prime target for new modes of prevention and treatment. Hepatitis C Virus (HCV) is the predominant risk factor for HCC in the US and Europe. Multiple epidemiological studies showed that sustained virological responses (SVR) following treatment with the powerful direct acting antivirals (DAAs), which have replaced interferon-based regimes, do not eliminate tumor development. We aimed to identify an HCV-specific pathogenic mechanism that persists post SVR following DAAs treatment. We demonstrate that HCV infection induces genome-wide epigenetic changes by performing chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) for histone post-translational modifications that are epigenetic markers for active and repressed chromatin. The changes in histone modifications correlate with reprogramed host gene expression and alter signaling pathways known to be associated with HCV life cycle and HCC. These epigenetic alterations require the presence of HCV RNA or/and expression of the viral proteins in the cells. Importantly, the epigenetic changes induced following infection persist as an "epigenetic signature" after virus eradication by DAAs treatment, as detected using in vitro HCV infection models. These observations led to the identification of an 8 gene signature that is associated with HCC development and demonstrate persistent epigenetic alterations in HCV infected and post SVR liver biopsy samples. The epigenetic signature was reverted in vitro by drugs that inhibit epigenetic modifying enzyme and by the EGFR inhibitor, Erlotinib. This epigenetic "scarring" of the genome, persisting following HCV eradication, suggest a novel mechanism for the persistent pathogenesis of HCV after its eradication by DAAs. Our study offers new avenues for prevention of the persistent oncogenic effects of chronic hepatitis infections using specific drugs to revert the epigenetic changes to the genome.
Source: PLoS Genetics
Authors: Shira Perez(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review & editing), Antony Kaspi(Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft), Tom Domovitz(Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization), Ateret Davidovich(Data curation, Formal analysis, Investigation, Validation, Visualization), Anat Lavi-Itzkovitz(Formal analysis, Software), Tomer Meirson(Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft), Jacinta Alison Holmes(Resources), Chia-Yen Dai(Resources), Chung-Feng Huang(Resources), Raymond T. Chung(Funding acquisition, Resources), Assy Nimer(Resources), Assam El-Osta(Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Gur Yaari(Formal analysis, Software), Salomon M. Stemmer(Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision), Ming-Lung Yu(Data curation, Project administration, Resources, Supervision), Izhak Haviv(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Meital Gal-Tanamy(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing)
Institutions: Bar-Ilan University, Monash University, Harvard University, Massachusetts General Hospital, Kaohsiung Medical University, Kaohsiung Medical University Chung-Ho Memorial Hospital, Western Galilee Hospital, Chinese University of Hong Kong, Prince of Wales Hospital, Tel Aviv University, Rabin Medical Center, National Sun Yat-sen University, National Yang Ming Chiao Tung University
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,350
Funders: Leona M. and Harry B. Helmsley Charitable Trust, European Commission, Israel Cancer Association, Israel Science Foundation, National Institutes of Health, Medical Research Council, National Health and Medical Research Council, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G3606678800, G5231292050, G6027816933, Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy, Patient-Oriented Research on Hepatitis in Special Populations, Durable Alteration of the Human Immune system after Infection or Immunotherapy
OpenAlex ID: W2949406476
